These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27745633)

  • 1. Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa.
    Wong D; Walsh S; Alhusayen R
    J Am Acad Dermatol; 2016 Nov; 75(5):1059-1062. PubMed ID: 27745633
    [No Abstract]   [Full Text] [Related]  

  • 2. Is it worthy to treat hidradenitis suppurativa with adalimumab in patients with melanoma and other debilitating systemic diseases? A series of clinical dilemmas.
    Zhao CY; Fernández-Peñas P
    Australas J Dermatol; 2018 Nov; 59(4):e297-e298. PubMed ID: 29672833
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V; Mrowietz U
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on Hidradenitis Suppurative (Part II): Treatment.
    Martorell A; García FJ; Jiménez-Gallo D; Pascual JC; Pereyra-Rodríguez J; Salgado L; Villarrasa E
    Actas Dermosifiliogr; 2015 Nov; 106(9):716-24. PubMed ID: 26277040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hidradenitis suppurativa (acne inversa): management of a recalcitrant disease.
    Lam J; Krakowski AC; Friedlander SF
    Pediatr Dermatol; 2007; 24(5):465-73. PubMed ID: 17958790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab (Humira°) and hidradenitis suppurativa.
    Prescrire Int; 2017 Apr; 26(181):94-96. PubMed ID: 30730659
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment of hidradenitis suppurativa in the setting of Crohn disease with combination adalimumab and ustekinumab.
    Cline A; Pichardo RO
    Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.
    Diamantova D; Lomickova I; Cetkovska P
    Acta Dermatovenerol Croat; 2014; 22(4):291-3. PubMed ID: 25580790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience of the use of adalimumab in the management of hidradenitis suppurativa. Comparison of response rates with Crohn disease.
    Moyano B; Clemente A; Marín-Jiménez I; Martorell A
    Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():43-50. PubMed ID: 28081769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
    Kimball AB; Sobell JM; Zouboulis CC; Gu Y; Williams DA; Sundaram M; Teixeira HD; Jemec GB
    J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):989-94. PubMed ID: 26201313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hidradenitis Suppurativa: Rapid Evidence Review.
    Wipperman J; Bragg DA; Litzner B
    Am Fam Physician; 2019 Nov; 100(9):562-569. PubMed ID: 31674740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hidradenitis suppurativa and Crohn's disease: two cases that support an association.
    Yazdanyar S; Miller IM; Jemec GB
    Acta Dermatovenerol Alp Pannonica Adriat; 2010 Oct; 19(3):23-5. PubMed ID: 20976417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab versus Rifampicin Plus Clindamycin for the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Retrospective Study.
    Marasca C; Annunziata MC; Villani A; Volpe S; Marasca D; Fabbrocini G
    J Drugs Dermatol; 2019 May; 18(5):437-438. PubMed ID: 31141853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience.
    Bettoli V; Manfredini M; Calamo G; Forconi R; Bencivelli D; Mantovani L; Pellacani G; Corazza M
    Dermatol Ther; 2018 Nov; 31(6):e12737. PubMed ID: 30295378
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceutical Benefits Scheme listing of adalimumab for hidradenitis suppurativa: Is hidradenitis suppurativa a life-changing drug or does lifestyle change the drug?
    Vekic DA; Frew JW
    Australas J Dermatol; 2018 Aug; 59(3):e243-e244. PubMed ID: 29285755
    [No Abstract]   [Full Text] [Related]  

  • 16. Adalimumab (Humira
    Gupta AK; Cernea M; Abramovits W; Vincent KD
    Skinmed; 2016; 14(4):291-294. PubMed ID: 27784520
    [No Abstract]   [Full Text] [Related]  

  • 17. Adalimumab: A Review in Hidradenitis Suppurativa.
    Kim ES; Garnock-Jones KP; Keam SJ
    Am J Clin Dermatol; 2016 Oct; 17(5):545-552. PubMed ID: 27665300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring treatment response to adalimumab in hidradenitis suppurativa patients: An observational study.
    Kok Y; Nicolopoulos J; Braue A; Kern JS; Varigos G; Dolianitis C
    Australas J Dermatol; 2020 Aug; 61(3):292-294. PubMed ID: 32065658
    [No Abstract]   [Full Text] [Related]  

  • 19. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
    J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa.
    Gupta AK; Studholme C
    Skin Therapy Lett; 2016 Jul; 21(4):1-4. PubMed ID: 27388530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.